Re: FDA BRUDAC 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for Research

We read this article with interest. As mentioned by the authors, only 2 FDA (U.S. Food and Drug Administration) approved therapies for interstitial cystitis/bladder pain syndrome (IC/BPS) currently exist: oral pentosan polysulfate sodium (PPS) and intravesical dimethyl sulfoxide. We wish to alert readers to a concerning new observation of vision threatening retinal changes associated with long-term exposure to PPS. We recently reported our findings of retinal pigmentary changes in 6 patients undergoing long-term therapy with PPS.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Letter to the Editor/Errata Source Type: research